AC Immune (NASDAQ:ACIU - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect AC Immune to post earnings of ($0.22) per share and revenue of $0.32 million for the quarter.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.99 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AC Immune Price Performance
Shares of AC Immune stock traded up $0.04 during trading hours on Wednesday, reaching $1.66. The company's stock had a trading volume of 172,857 shares, compared to its average volume of 323,240. AC Immune has a one year low of $1.43 and a one year high of $4.98. The firm has a 50 day moving average price of $1.86 and a 200-day moving average price of $2.54. The stock has a market cap of $166.68 million, a P/E ratio of -3.61 and a beta of 1.62.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on ACIU shares. HC Wainwright lowered their price objective on AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. StockNews.com lowered shares of AC Immune from a "buy" rating to a "hold" rating in a research note on Monday.
View Our Latest Research Report on ACIU
AC Immune Company Profile
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
